Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy

抗癌生物科学公司欢迎新投资者进入种子融资轮,使融资总额超过3100万美元,以推进癌症治疗的合成致命方法

2021-10-14 22:00:11 BioSpace

本文共1399个字,阅读需4分钟

CHENGDU, China---- Anticancer Bioscience , pioneers in synthetic lethal approaches to precision oncology, announced today that it had secured an additional CNY 68.4 million from new Chinese investors. The seed extension financing was led by Three Rivers Capital, who joins existing private Chinese investors. The total raised in the seed round is now over USD31 million . The proceeds will be mainly used to accelerate the preclinical development of the company’s two most advanced programs, MYC-synthetic lethal and contact inhibition restoration. The funds will also be used to optimize lead compounds for polyploidy-synthetic lethal therapy and to identify additional lead compounds for the company’s contact inhibition restoration approach to combatting cancer. ACB is applying synthetic lethal approaches to develop targeted cancer therapies. These have the potential to be much safer and more effective than current therapies. ACB has access to world-leading cancer biology expertise and drug discovery platforms that enable the company to identify novel compounds that can target both genetic and epigenetic vulnerabilities of cancer cells. ACB has bespoke chemical compound libraries and has invested in developing one of the world’s largest natural product libraries, providing a rich screening resource for potential cancer therapeutics. Commenting on the financing, Dun Yang PhD, Founder, President, and CEO of ACB said, “This successful financing round is a further strong endorsement of our innovative approach to identifying first-in-class and best-in-class therapeutics for the treatment of cancer, using synthetic lethal strategies. It underlines our progress over the past months and will help accelerate our five drug discovery programs through optimization to candidate selection and IND enabling studies. We aim to initiate two clinical trials in 2022.” Xiaoyin Chen, Investment Director at Three Rivers Capital said: “ACB is an emerging innovative biotech with global competitiveness. We firmly believe that only revolutionary innovations in drug discovery and development can generate great clinical benefits and value. ACB utilizes its unique small molecule libraries and screening approaches, combined with its multiple proprietary platform technology based on synthetic lethality, to develop broad-spectrum anti-cancer drugs and strives to become the pioneer in developing novel and next-generation cancer therapies.” ACB will be presenting its innovative drug discovery platforms and pipeline at the LSX Inv€$tival Showcase in November. -ENDS- About Anticancer Bioscience https://www.anticancerbio.com/ Anticancer Bioscience (ACB) is an international private company, commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY200m (~USD31m) and has ~50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA. Follow us on LinkedIn and Twitter. About Three Rivers Capital Three Rivers Capital was established in June 2019. With more than ¥3 billion under management, Three Rivers Capital is actively investing in three strategic sectors: new medicines, new fields of consumption and advanced technology and manufacturing. View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005021/en/ At the company Anticancer Bioscience bd@anticancerbio.com Media relations Scius Communications Sue Charles +44 (0) 7968 726585 sue@sciuscommunications.com Daniel Gooch +44 (0)7747875479 daniel@sciuscommunications.com Source: Anticancer Bioscience View this news release online at: http://www.businesswire.com/news/home/20211014005021/en
中国成都----抗癌生物科学,精密肿瘤学合成致命方法的先驱,今天宣布,它已经从新的中国投资者那里获得了6840万元的额外资金。种子扩展融资由三江资本牵头,该公司加入了现有的中国私人投资者。种子轮筹集的资金总额现已超过3100万美元。 所得款项将主要用于加速该公司两个最先进项目的临床前开发,即Myc合成致死和接触抑制恢复。这笔资金还将用于优化多倍体合成致命疗法的先导化合物,并为该公司对抗癌症的接触抑制恢复方法识别额外的先导化合物。 ACB正在应用合成致命方法来开发靶向癌症疗法。这些有可能比目前的疗法更安全、更有效。ACB拥有世界领先的癌症生物学专业知识和药物发现平台,使该公司能够识别能够针对癌细胞遗传和表观遗传弱点的新化合物。ACB拥有定制的化合物库,并投资开发了世界上最大的天然产物库之一,为潜在的癌症治疗提供了丰富的筛选资源。 ACB创始人、总裁兼首席执行官杨盾博士在评论此次融资时表示:“此次融资成功,进一步有力地支持了我们的创新方法,即使用合成致命策略来识别一流和最佳的癌症治疗方法。它强调了我们在过去几个月中取得的进展,并将通过优化候选筛选和IND支持研究来帮助加快我们的五个药物发现项目。我们的目标是在2022年启动两项临床试验。“ 三江资本投资总监陈晓音表示:“ACB是一种具有全球竞争力的新兴创新生物技术。我们坚信,只有在药物发现和开发方面进行革命性的创新,才能产生巨大的临床效益和价值。ACB利用其独特的小分子库和筛选方法,结合其基于合成杀伤力的多专有平台技术,开发广谱抗癌药物,并努力成为开发新型和下一代癌症疗法的先驱。“ ACB将在11月的LSX Inv Tival展示会上展示其创新药物发现平台和管道。 -结束- 关于抗癌生物科学https://www.anticancerbio.com/ 抗癌生物科学(ACB)是一家国际私营公司,将中国在J.Michael Bishop癌症研究所进行的世界领先的癌症研究中出现的发现商业化。ACB于2016年在中国成都成立,拥有精确肿瘤学合成致命方法的先驱和MYC生物学和细胞分裂方面的专家。ACB是基于创始人杨敦博士和他的诺贝尔奖导师J.Michael Bishop博士20多年的合作研究。公司已在中国成都、印度海德拉巴、澳大利亚悉尼、英国圣安德鲁斯和美国旧金山等地募集资金2亿元(约合3100万美元),拥有员工约50人。 在领英和推特上关注我们。 关于三江都城 三江资本成立于2019年6月。三江资本管理着超过30亿日元的资金,正积极投资于三个战略领域:新药、新消费领域和先进技术与制造。 在businesswire.com查看源代码版本:https://www.businesswire.com/news/home/20211014005021/en/ 在公司 抗癌生物科学 @anticancerbio.com 媒体关系 Scius通信 苏·查尔斯 +44(0)7968 726585 sue@sciuscommunications.com 丹尼尔·古奇 +44(0)7747875479 @sciuscommunications.com 来源:《抗癌生物科学》 在网上查看此新闻稿: http://www.businesswire.com/news/home/20211014005021/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文